Why Oscar Health (OSCR) Is Up 9.6% After Issuing 2026 Profit Guidance And Securing New Credit Facility
Oscar Health (OSCR) saw its stock rise 9.6% after announcing full-year 2026 profit guidance, targeting $18.7 billion to $19.0 billion in revenue and $250 million to $450 million in operational earnings. This positive outlook follows a $443.15 million net loss in 2025. The company also secured a new $475.0 million revolving credit facility, which, alongside rapid membership growth and technology-driven efficiency, aims to help Oscar Health achieve profitability in 2026.
Oscar Health, Inc. SEC 10-K Report
Oscar Health, Inc. has released its 2025 Form 10-K report, revealing a significant increase in total revenue to $11,701 million, but also a net loss of $(443) million, primarily due to increased medical expenses and market morbidity. The company expanded its coverage to 18 states and grew its membership to approximately 2.0 million, with strategic acquisitions aimed at enhancing its direct enrollment technology and focusing on the ICHRA market. Oscar faces challenges including regulatory changes, competitive pressures, and interest rate fluctuations, but plans to leverage its technology and strategic capital management to drive future growth and efficiency.
Oscar Health, Inc. (NYSE:OSCR) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Oscar Health, Inc. reported disappointing yearly results last week, with revenues missing expectations and statutory earnings falling significantly short. However, analysts have since upgraded their earnings model, now forecasting Oscar Health to become profitable in 2027 and expecting higher revenues that will grow faster than the wider industry. Despite the upgraded estimates and improved outlook, the consensus price target remains unchanged at US$15.40, indicating no long-term impact on the company's valuation from the recent performance.
New Forecasts: Here's What Analysts Think The Future Holds For Oscar Health, Inc. (NYSE:OSCR)
Analysts have significantly upgraded their revenue forecasts for Oscar Health, Inc. (NYSE:OSCR) for 2026, now expecting revenues of US$16 billion and a return to profitability with US$0.17 earnings per share, instead of previous loss predictions. Despite these improved business outlooks, their price target for the stock remains unchanged. The company is anticipated to continue its high revenue growth rate, outperforming the broader industry.
Oscar Health Q4 Loss Of US$353 Million Tests Profitability Turnaround Narrative
Oscar Health reported a Q4 FY 2025 loss of US$353 million, bringing its trailing twelve-month loss to US$443.2 million, which challenges the company's projected turnaround to profitability. Despite bullish forecasts for strong earnings growth and a move to profit within three years, recent quarterly performance shows significant swings from profit to loss. The company's P/S ratio of 0.3x is below the industry average, reflecting slower forecast revenue growth, putting pressure on the earnings growth narrative to materialize.
Oscar Health Inc (NYSE:OSCR) Posts Wider Q4 Loss on Surging Medical Costs, Shares Drop
Oscar Health Inc. reported a wider-than-expected Q4 loss due to a significant increase in medical costs, causing its shares to drop. The company's medical loss ratio rose to 95.4%, driven by higher market morbidity and healthcare utilization, despite strong membership growth. Looking ahead, Oscar Health projects a return to operational profitability in 2026, backed by a new credit facility, but faces a cautious revenue outlook compared to analyst expectations.
Earnings Flash (OSCR) Oscar Health, Inc. Reports Q4 Revenue $2.81B, vs. FactSet Est of $3.11B
Oscar Health, Inc. (OSCR) reported its Q4 revenue at $2.81 billion, falling short of the FactSet estimate of $3.11 billion. The company also posted a Q4 loss of $1.24 per share, which was wider than the FactSet estimate of an $0.89 loss per share. Despite the Q4 revenue miss, Oscar Health provided earnings guidance for the full year 2026, expecting revenue in the range of $18.7 billion to $19 billion.
Oscar Health’s First Profit Shifts Focus To Growth, Costs And Volatility
Oscar Health (NYSE:OSCR) has reported its first-ever profit, attributing the milestone to operational restructuring, stricter cost control, and strong membership trends. The technology-focused health insurer's shift to profitability is a significant development in the broader health insurance sector, which grapples with rising medical costs and regulatory attention. For investors, the focus now turns to Oscar's ability to sustain these improvements, manage medical costs, and retain members, with its shares currently trading below analyst targets and experiencing recent volatility.
Oscar Health Faces CMS Medicare Changes And Questions On Growth Outlook
Oscar Health is facing new regulatory challenges due to a proposed minimal increase in Medicare Advantage payment rates and tighter risk adjustment rules from CMS. These changes could significantly impact Oscar Health's data-driven Medicare Advantage and virtual care offerings, raising questions about how the company will adjust its benefits, pricing, and care management strategies. Investors are closely watching how Oscar Health, already experiencing some stock price volatility, will adapt to these proposed regulations amid broader industry trends of rising medical costs.
Oscar Health (OSCR) Valuation Check As Blue Square Exit And Barclays Upgrade Pull Sentiment In Opposite Directions
Oscar Health (OSCR) is experiencing conflicting market signals, with Blue Square Asset Management selling its entire stake while Barclays upgraded its rating. Despite recent share price choppiness, a popular narrative suggests Oscar Health is significantly undervalued at $45.34 compared to its current price of $15.68, driven by membership growth, its proprietary +Oscar platform, and substantial cash reserves. However, this upside is balanced against ongoing net losses and potential slowdowns in growth.
Precision Trading with Oscar Health Inc. Class A (OSCR) Risk Zones
This article provides a precision trading analysis for Oscar Health Inc. Class A (OSCR), highlighting a weak near-term sentiment that could precede shifts in its mid and long-term outlook. It identifies an exceptional 73.2:1 risk-reward setup targeting a 20.0% gain versus 0.3% risk, along with three distinct trading strategies (Position, Momentum Breakout, Risk Hedging) tailored for different risk profiles. The analysis also includes multi-timeframe signal strengths and key support and resistance levels generated by AI models.
Why Oscar Health (OSCR) Is Down 9.9% After Mixed Results And An Institutional Investor Exit - And What's Next
Oscar Health (OSCR) shares fell 9.9% following mixed quarterly results, including a revenue miss balanced by raised operating income guidance, and an institutional investor's complete exit. The market is weighing the company's path to profitability and execution risks despite its technology-focused insurance model. Investor sentiment is divided, with fair value estimates varying widely, underscoring the uncertainty surrounding the stock's future.
Oscar Health Faces Full Exit By Blue Square As Price Nears Target
Blue Square Asset Management has fully divested its stake in Oscar Health (NYSE:OSCR), selling its complete holding. This institutional exit comes as Oscar Health's stock price, currently at US$15.92, is trading slightly above the analyst target of US$15.78. The move highlights the importance for investors to monitor other large shareholders and upcoming company disclosures, especially given the stock's recent volatility and 6.8% momentum gain over 30 days.
Oscar Health (OSCR) Is Up 5.2% After ACA Subsidy Extension Supports Core Exchange Business Model
Oscar Health (OSCR) saw a 5.2% jump after the U.S. House of Representatives extended Affordable Care Act (ACA) premium subsidies for three more years. This extension directly supports Oscar Health's core ACA-focused business model, reducing concerns about potential market shrinkage due to expiring subsidies and reinforcing membership resilience. While policy risk has eased, investors will be closely watching the upcoming earnings release on February 10, 2026, for updates on membership trends and medical loss ratios, as higher claims costs could still impact margins.
Oscar Health CTO Schlosser sells $406k in shares By Investing.com
Oscar Health's President of Technology & CTO, Mario Schlosser, sold 23,038 shares of Class A Common Stock for over $406,000 on January 8, 2026, under a pre-arranged trading plan. Following the sale, Schlosser retains significant direct and indirect ownership in the company. This transaction comes amidst several analyst upgrades and positive outlooks for Oscar Health, driven by anticipated increased health insurance exchange enrollments and potential extensions of Obamacare subsidies.
Oscar Health CTO Schlosser sells $406k in shares By Investing.com
Mario Schlosser, Oscar Health's CTO and President of Technology, sold 23,038 shares of Class A Common Stock for over $406,000 on January 8, 2026, as part of a pre-arranged trading plan. This transaction followed the conversion of an equivalent number of Class B shares. The sale comes amidst positive analyst upgrades and a strong outlook for Oscar Health, particularly concerning health insurance exchange enrollments and potential Obamacare subsidy extensions.
Oscar Health CTO Schlosser sells $406k in shares By Investing.com
Mario Schlosser, Oscar Health's CTO, sold 23,038 shares of Class A Common Stock for $406,620 on January 8, 2026, under a pre-arranged trading plan. Following the sale, he retains significant direct and indirect holdings in the company. This transaction comes amidst several positive analyst upgrades and favorable policy outlooks for Oscar Health, including improved profitability forecasts and expected enrollment growth in health insurance exchanges.
Oscar Health CTO Schlosser sells $406k in shares
Oscar Health CTO Mario Schlosser sold 23,038 shares of Class A Common Stock for $406,620 on January 8, 2026, under a pre-arranged trading plan. Following this sale, Schlosser retains substantial direct and indirect holdings in the company. The transaction aligns with recent positive analyst upgrades and potential policy changes, including a possible extension of Obamacare subsidies, which have generally improved Oscar Health's market outlook.
Oscar Health CTO Schlosser sells $406k in shares By Investing.com
Oscar Health CTO Mario Schlosser sold 23,038 shares of Class A Common Stock for over $406,000 on January 8, 2026, under a pre-arranged trading plan. This sale follows several recent positive developments for Oscar Health, including multiple analyst upgrades and a potential extension of Obamacare subsidies, indicating strong market interest and improved outlooks for the company. Schlosser retains substantial holdings in both Class A and Class B common stock.
Oscar Health CTO Schlosser sells $406k in shares
Oscar Health CTO Mario Schlosser sold 23,038 shares of Class A Common Stock for over $406,000 on January 8, 2026, as part of a pre-arranged trading plan. This transaction followed the conversion of Class B shares to Class A. The article also highlights recent positive analyst upgrades for Oscar Health, reflecting improved profitability outlooks and better-than-expected enrollment projections in health insurance exchanges.
Oscar Health CTO Schlosser sells $406k in shares By Investing.com
Oscar Health's CTO, Mario Schlosser, sold 23,038 shares of Class A Common Stock for approximately $406,620 on January 8, 2026, as part of a pre-arranged trading plan. Following the sale, Schlosser retains a significant number of Class A and Class B shares. This transaction comes amidst several recent analyst upgrades and positive industry developments for Oscar Health.
Oscar Health president Schlosser sells $1.3 million in shares
Oscar Health's President of Technology & CTO, Mario Schlosser, sold 76,962 shares of Class A Common Stock for approximately $1.3 million on January 6, 2026. This sale occurred concurrently with the conversion of an equal number of Class B shares to Class A shares. The company has also announced new health insurance options in South Florida for 2026 and received upgraded stock ratings and price targets from Piper Sandler and Barclays, reflecting a positive outlook despite potential market challenges.
Oscar Health stock surges over 6% after hours as House backs Obamacare subsidies
Oscar Health's stock surged over 6% in after-hours trading following the House of Representatives' support for continued Obamacare subsidies. This move is seen as beneficial for health insurance providers like Oscar Health, which operates within the Affordable Care Act's framework. The increased certainty around these subsidies is likely driving investor confidence.
A Look At Oscar Health’s Valuation As Barclays Upgrade Sparks Fresh Interest In Insurers
Barclays' recent upgrade of Oscar Health (OSCR) has drawn fresh attention to the insurer, citing attractive pricing, reduced policy risk, and potential profit margin expansion. Despite a recent share price rebound, Oscar Health is currently trading at a slight premium to the average analyst target price, suggesting a potential overvaluation based on current models. However, its low P/S ratio compared to the broader insurance sector could also indicate a mispricing or reflect the delayed path to profitability.
Oscar Health Stock Surges Over 6% After Hours As House Backs Obamacare Subsidies
Oscar Health Inc. shares surged over 6% in after-hours trading following the U.S. House of Representatives' vote to extend Affordable Care Act (ACA) subsidies for three years, despite a recent insider share sale. The bill, which now moves to the Senate, aims to renew Obamacare tax credits that expired in late 2025. This legislative development overshadowed concerns about insider trading and Republican criticism regarding the extension's potential impact on premiums and the national debt.
Why Oscar Health (OSCR) Is Up 14.2% After Barclays Eases Concerns On Risk And Margins – And What's Next
Oscar Health (OSCR) share price increased by 14.2% after Barclays upgraded its rating to Equalweight, easing concerns about expiring subsidies and sector pressures. Barclays believes the market might have over-discounted risks and sees potential for profit margin expansion in managed care. The article discusses Oscar Health's investment narrative, including its tech-focused model, AI-powered tools, and expansion plans, and touches upon various fair value estimates from the Simply Wall St Community.
Trading the Move, Not the Narrative: (OSCR) Edition
This article analyzes Oscar Health Inc. Class A (OSCR) using AI models to provide trading strategies. It highlights weak near and mid-term sentiment but a strong long-term outlook, offering position, momentum, and risk hedging strategies for investors. The analysis includes support and resistance levels across different time horizons.
Looking Into Oscar Health Inc's Recent Short Interest
Oscar Health Inc (NYSE: OSCR) has seen an 8.81% decrease in short interest, with 28.56 million shares sold short, representing 12.42% of its float. This decline in short interest can suggest a more bullish sentiment towards the stock. Despite this, Oscar Health Inc's short interest is still higher than the peer group average of 3.44%.
Oscar Health (OSCR): Reassessing Valuation as Regulatory and Competitive Pressures Intensify in Georgia
Oscar Health (OSCR) is facing renewed scrutiny due to intensifying regulatory and competitive pressures, particularly in the Georgia market, which could impact its profitability. Despite a recent recovery in share price and strong longer-term shareholder returns, the stock's current valuation, slightly above Wall Street targets, raises questions about whether it is overvalued amidst these risks. Analysts have a consensus price target of $11.143, with a fair value narrative suggesting slight overvaluation, while market multiples indicate potential value.
Oscar Health (OSCR): Reassessing Valuation After New Analyst Coverage and Broward Health Network Expansion
Oscar Health (OSCR) has gained attention due to new analyst coverage from Stephens and Co. and a partnership with Broward Health. While a narrative fair value suggests the stock is 15.7% overvalued at $14.38, its price-to-sales ratio indicates it might be undervalued compared to peers, implying market sentiment is overly cautious. The article suggests investors consider both the promising growth forecasts and the current market multiples when evaluating OSCR.
Can Oscar Health (OSCR) Turn Claims Volatility Into an Edge With Its Tech-Driven Platform?
Oscar Health, despite facing higher-than-expected claims losses earlier in the year, saw a 23% revenue increase in Q3 2025 and has growing membership exceeding 2 million, supported by its tech-driven platform. The company's 2025 guidance projects significant revenue growth and a reduced loss from operations, although analyst views on its fair value vary widely. Investors are closely monitoring medical loss ratio normalization and execution on pricing to gauge the company's long-term profitability.
Oscar Health Stock Soars: What’s Behind the Surge?
Oscar Health Inc. (NYSE: OSCR) stock surged 8.49% recently, reflecting positive market sentiment driven by analyst upgrades, particularly from Piper Sandler. Despite past net losses, strong revenue consistency, technological innovations like AI-driven health solutions, and strategic regional expansions are fueling investor optimism. The company aims for profitability by 2026 through margin expansion strategies, navigating a competitive and regulated healthcare landscape.
Oscar Health (OSCR): Revisiting Valuation After Analyst Upgrade and Bullish Options Signal Growing Investor Confidence
Oscar Health (OSCR) has seen a surge in investor confidence following bullish options activity and an analyst upgrade, despite still reporting losses. The company's stock has shown strong year-to-date and three-year returns, sparking debate on whether its current valuation is justified. While some metrics suggest Oscar Health is overvalued, others like its low price-to-sales ratio indicate potential undervaluation.
Why Oscar Health (OSCR) Is Up 33.3% After Analysts Highlight Resilience Amid ACA Subsidy Uncertainty
Oscar Health (OSCR) saw a significant stock boost after analysts at Piper Sandler upgraded its rating, citing the company's resilience in gaining market share and improving profitability despite potential ACA subsidy uncertainties. The prospect of extended Affordable Care Act subsidies is highlighted as a key factor that could provide stability and consistent membership for Oscar Health, influencing its investment narrative positively. While Oscar Health shows growth in revenue and membership, profitability remains a challenge due to high operating costs.
Oscar Health (OSCR): Evaluating Valuation After Policy Proposal Sparks Investor Optimism
Oscar Health (OSCR) shares surged after news of a potential two-year extension of Obamacare subsidies and expanded eligibility, sparking investor optimism despite the company's valuation being deemed "Overvalued" by analysts at $12.88. While the stock's one-year return is modest, its three-year return shows significant growth. The article also notes Oscar Health's low price-to-sales ratio compared to industry peers, suggesting potential for upside if market sentiment shifts.
Oscar Health Q3 Loss Deepens Beyond Expectations
Oscar Health Inc. reported a net loss of $0.53 per share in Q3, exceeding analysts' expectations of a $0.48 loss and experiencing a 15.43% stock price decline. The company's financials reveal negative profit margins and a high leverage ratio, raising concerns among investors. Strategic changes focused on cost rationalization, new market ventures, or advanced AI models are suggested for Oscar Health to navigate its financial challenges and return to profitability.
Oscar Health (OSCR) Stock Is Soaring: Here's Why
Oscar Health (OSCR) stock is soaring due to a bullish analyst upgrade from Piper Sandler, which nearly doubled its price target, and regulatory tailwinds from the White House's impending framework to extend Affordable Care Act subsidies. This extension is crucial for Oscar's individual exchange market business model, preventing a fiscal cliff that would have led to increased premiums and a sicker risk pool. Despite a Q3 revenue miss and deeper operating loss, legislative clarity from the Healthcare Price Cuts Act is converting a major structural risk into a growth catalyst for the company.
OSCR Stock Price and Chart — NYSE:OSCR
This article provides a comprehensive overview of Oscar Health, Inc. (NYSE: OSCR) stock, including its current price, performance across various timeframes, key financial metrics, and upcoming earnings dates. It also features a section with market sentiment ("Ideas") and technical analysis from various contributors, offering different perspectives on the stock's future movement. The company information, related stocks, and ETF holdings are presented to give a holistic view of OSCR.
Oscar Health Announces Financial Results for Third Quarter 2025 and Reaffirms 2025 Guidance
Oscar Health, Inc. released its financial results for the third quarter ended September 30, 2025, reaffirming its full-year 2025 guidance across all metrics. Despite an increase in medical loss ratio impacting operational loss, the company reported growth in total revenue and membership, driven by disciplined pricing and geographic expansion. Oscar Health aims to return to profitability in 2026 by focusing on affordable, innovative plans and a superior member experience.
How Oscar Health Inc. Class A (OSCR) Affects Rotational Strategy Timing
Oscar Health Inc. Class A (OSCR) is showing weak near and mid-term sentiment but a strong long-term outlook, with resistance currently being tested. The article details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to manage different risk profiles. This analysis helps understand how OSCR's market dynamics influence rotational strategy timing for investors.
Oscar Health (NYSE:OSCR) Surges on Narrowed Loss and Reaffirmed Guidance Despite Q3 Revenue Miss
Oscar Health (NYSE:OSCR) reported mixed Q3 2025 financial results, with revenue missing expectations but a narrower net loss. The company's stock surged over 7% pre-market due to reaffirmed full-year guidance, strong membership growth, and improved cost efficiency. Investors are focusing on Oscar Health's operational improvements and its confidence in achieving profitability by 2026 despite the quarterly revenue shortfall.
Oscar Health (NYSE:OSCR) Shares Down 9.5% - What's Next?
Oscar Health's stock (NYSE:OSCR) dropped 9.5% to $19.03 with reduced trading volume. This decline follows recent analyst downgrades and lower price targets, notably Barclays setting a target of $11. Despite a 29% year-over-year revenue increase, the company reported a negative EPS of ($0.89) for the last quarter.
Oscar Health Stock (OSCR) Opinions on $410M AI Funding and Revenue Guidance - Quiver Quantitative
Oscar Health (OSCR) is receiving mixed opinions following its $410 million AI funding initiative and revised 2025 revenue guidance of $1.12–$1.13 billion. Discussions highlight optimism for technology-driven growth but also concerns about stock volatility. The company's focus on profitability drivers like reducing medical loss ratios and SG&A expenses is also noted, while insider sales and varied analyst ratings provide further context.
Bayforest Capital Ltd Has $452,000 Position in Oscar Health, Inc. $OSCR
Bayforest Capital Ltd significantly increased its stake in Oscar Health, Inc. by 188.7% to $452,000, despite the company facing multiple analyst downgrades and a "Strong Sell" rating tendency. Insider transactions show CEO Mario Schlosser reducing his ownership by 44.08%. Oscar Health reported quarterly earnings that beat consensus but had revenue slightly below estimates, with analysts predicting 0.69 EPS for the current year.
Oscar Health Hits Day High with 8.68% Surge Amid Market Decline - Markets Mojo
Oscar Health, Inc. experienced an 8.68% stock surge, reaching an intraday high of USD 20.49, contrasting with a 2.71% decline in the S&P 500 on the same day. Despite outperforming the S&P 500 year-to-date with a 51.79% increase, the company has faced a negative return of 19.32% over the past year. Oscar Health, with a market capitalization of USD 5,250 million, operates as a small-cap entity in the healthcare services industry.
Oscar Health, Inc. (NYSE:OSCR) Given Consensus Recommendation of "Strong Sell" by Analysts
Oscar Health, Inc. (NYSE:OSCR) has received a consensus "Strong Sell" recommendation from analysts, with an average twelve-month price target of $12.64, significantly below its recent opening price of $20.36. Insider Mario Schlosser sold a substantial portion of his shares, indicating potential concerns. The company's financials show a negative P/E ratio and recent quarterly losses, despite revenue growth.
Udine Wealth Management Inc. Makes New Investment in Oscar Health, Inc. $OSCR
Udine Wealth Management Inc. has acquired a new position in Oscar Health, Inc. (NYSE:OSCR), purchasing 61,472 shares valued at approximately $1.318 million. This investment makes Oscar Health the firm's 28th largest holding, despite the stock experiencing an 8.4% decline and Wall Street analysts lowering their price targets. Other institutional investors have also adjusted their positions in Oscar Health, with the company currently trading at $18.81 with a market capitalization of $4.86 billion.
Janney Montgomery Scott LLC Increases Position in Oscar Health, Inc. $OSCR - MarketBeat
Janney Montgomery Scott LLC significantly increased its stake in Oscar Health, Inc. (NYSE:OSCR) by 32% in the second quarter, now holding 71,152 shares valued at $1,525,000. This increase comes amidst analyst downgrades, with Robert W. Baird cutting its price target to $14 and multiple analysts rating the stock as a "Sell". Additionally, insider Mario Schlosser sold a substantial number of shares, reducing his ownership by over 44%.
Oscar Health (OSCR): Assessing Valuation Following Major Insider Sale and Convertible Debt Announcement
Oscar Health (NYSE: OSCR) is under significant investor scrutiny following a major insider share sale by its CTO and a $355 million convertible senior notes offering. Despite previous strong gains, the stock has recently seen a decline, raising questions about its current valuation. While one narrative suggests the company is 65% overvalued with a fair value of $11.14, based on discounted cash flows, another view, using revenue multiples, indicates it could be cheap, but this needs further investigation.
Oscar Health plans to offer $350 million in convertible notes
Oscar Health, Inc. (NYSE:OSCR) announced plans to offer $350 million in convertible senior subordinated notes due 2030 in a private offering. The healthcare technology company, with a $4.87 billion market cap, intends to use the proceeds for general corporate purposes including AI initiatives and enhancing member experiences, and to offset potential share dilution through capped call transactions. Despite recent Q2 2025 earnings falling short of analyst expectations, the company reaffirmed its full-year guidance and serves approximately 2.0 million members.
